



Published in final edited form as:

Science. 2020 April 24; 368(6489): 424–427. doi:10.1126/science.aba6794.

Structure of a trapped radical transfer pathway within a ribonucleotide reductase holo complex

Gyunghoon Kang^{1,2}, Alexander T. Taguchi^{3,*}, JoAnne Stubbe^{2,3,†}, Catherine L. Drennan^{1,2,3,†}

¹Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge MA, United States

²Department of Biology, Massachusetts Institute of Technology, Cambridge MA, United States

³Department of Chemistry, Massachusetts Institute of Technology, Cambridge MA, United States

Abstract

Ribonucleotide reductases (RNRs) are a diverse family of enzymes that are alone capable of generating 2'-deoxynucleotides de novo and are thus critical in DNA biosynthesis and repair. The nucleotide reduction reaction in all RNRs requires the generation of a transient active site thiyl radical, and in class I RNRs this process involves a long-range radical transfer between two subunits, α and β . Due to the transient subunit association, an atomic resolution structure of an active $\alpha_2\beta_2$ RNR complex has been elusive. Here we use a doubly-substituted β_2 , E52Q/(2,3,5)-trifluorotyrosine122- β_2 to trap wildtype- α_2 in long-lived $\alpha_2\beta_2$ complex. We report the structure of this complex by cryo-electron microscopy to 3.6-Å resolution, allowing for structural visualization of a 32-Å-long radical transfer pathway that affords RNR activity.

One Sentence Summary:

A structure of the long-range radical transfer pathway within a ribonucleotide reductase.

Ribonucleotide reductases (RNRs) convert ribonucleotides into deoxyribonucleotides and generate the deoxyribonucleotide pools needed for DNA biosynthesis and repair (Fig. 1A, S1). Due to these activities, RNRs are drug targets, with several FDA-approved RNR inhibitors employed clinically in the treatment of various forms of cancer (1). For all RNR classes, catalysis entails formation of a protein-based thiyl radical species in the active site

[†]Corresponding author. stubbe@mit.edu (J.S.); cdrennan@mit.edu (C.L.D.).

^{*}Current address for ATT: RubrYc Therapeutics, San Carlos CA, United States

Author contributions: G.K. and A.T.T. performed sample optimization for cryo-EM sample preparation. G.K. collected and processed the cryo-EM data, and built and refined the structure. G.K., J.S., and C.L.D. wrote the manuscript. J.S. and C.L.D. supervised the research and led project conceptualization.

Competing interests: The authors declare no competing interests.

Data and materials availability: Atomic coordinates and cryo-EM map of the reported structure have been deposited to the Protein Data Bank (accession code 6W4X) and Electron Microscopy Data Bank (accession code EMD-21540), respectively.

Supplementary Materials:

Materials and Methods

Figures S1-S14

Tables S1-S4

(2). In the case of the prototypic class Ia RNR from *Escherichia coli*, the generation of this thiyl radical species occurs on the $\alpha 2$ subunit (C439 α •) and involves a long-range radical transfer from the $\beta 2$ subunit's diferric-tyrosyl radical cofactor (Y122 β •) (Fig. 1B (3)). The distance that radical species must travel has been estimated to be an incredibly long 35–40 Å, based both on pulsed electron-electron double resonance (PELDOR) spectroscopy (4) and on a docking model of an $\alpha 2\beta 2$ complex that was based on shape complementarity of the separate $\alpha 2$ and $\beta 2$ crystal structures (Fig. 1C, S2A) (5). Importantly, this radical transfer, which is proposed to occur through a series of reversible proton-coupled electron transfer (PCET) steps, does not involve typical electron-transfer cofactors, but instead requires a series of conserved aromatic amino acids (2, 3, 5, 6) (Fig. 1B). Key residue Y356 β has never been structurally visualized; this residue is located on the C-terminal β -tail (residues 341 β –375 β), which is disordered in all $\beta 2$ structures. The goal of this study is to provide a structure of the active $\alpha 2\beta 2$ state of an RNR that has the critical β -tail ordered and the intact PCET pathway visualized.

There are two main reasons why obtaining such a structure has eluded researchers. First, the $\alpha 2\beta 2$ interaction that affords thiyl radical generation is transient, with a k_{off} for $\beta 2$ from $\alpha 2$ of greater than 60 per sec (7). The PCET pathway is intact during the radical transfer process; however, following the return of the radical to $\beta 2$, the PCET pathway disassembles. Second, the active $\alpha 2\beta 2$ state is in equilibrium with an inactive $\alpha 4\beta 4$ state (8). The shifting of this equilibrium between active and inactive states is responsible for regulating RNR activity in response to deoxyribonucleotide levels in *E. coli* (Fig. S2B) (8). For these two reasons, the structure of the active form of RNR has been elusive, requiring some means of trapping the active state to slow subunit dissociation and limit oligomeric state change.

Here we succeed in trapping the active state of RNR by using a previously studied doubly-substituted E52Q/(2,3,5)-trifluorotyrosine122(F₃Y122)- $\beta 2$ (9) with wildtype- $\alpha 2$ in the presence of substrate GDP and specificity effector TTP (Fig. 1D). The overall resolution is 3.6 Å, with local resolution ranging from ~3.3 Å within the core of the protein complex to 5.5 Å on the $\alpha 2$ surface (Fig. S3, Table S1). Regions of highest resolution show clear density for side-chains (Fig. S4). Importantly, we further demonstrate that this RNR construct is active: it is capable of forming product (1 equivalent of dGDP per dimer), and it forms a pathway radical (Y356•) in a kinetically competent manner (Fig. S5). This structure addresses key questions about RNR and about biological PCET, including how PCET residues are arranged with respect to each other and to possible proton acceptors/donors; the molecular basis for the conversion of a disordered stretch of 20 amino acids into an ordered PCET pathway; why the PCET pathway disassembles after every round of turnover; the factors that trigger pathway disassembly and assembly; and to what degree the structure of an active RNR state looks like the docking model.

The first striking observation from our structure is that unlike the *E. coli* RNR symmetric docking model (Fig. 1C), the cryo-EM structure of the $\alpha 2\beta 2$ complex is asymmetric (Fig. 1D). The $\alpha 2$ - $\beta 2$ interface is formed primarily between one α monomer and $\beta 2$, and minimal interaction with the other α monomer (hereafter referred to as α') (Fig. 1D). This positioning of subunits precludes the simultaneous formation of two radical translocation pathways, which is consistent with prior evidence for half-sites reactivity such as the

observation that one equivalent of the cancer drug gemcitabine diphosphate inactivates both α monomers (10) We now see that only one α subunit can turnover at a time. Additionally, this finding of asymmetry is consistent with previous structural snapshots of class Ib RNRs (11, 12), the first of which is a structure that is best-described as $\beta 2$ dangling off of one α monomer (Fig. S2C) (11).

We are able to visualize all residues of the elusive β -tail, including Y356 and the ~ 20 residues within the ~ 35 residue-long β -tail (residues 341–375) that have been disordered in previous structures (Fig. 2A). Consistent with complex asymmetry, the tail of the other β monomer (hereafter referred to as β') is only resolved up to residue 341 (of 375). The ordered β -tail extends far into the active site cavity in α , coming into direct van der Waals contact with substrate before making a sharp turn and extending back toward the β subunit, and finally looping around to a groove on the side of α (Fig. 2A, S6). This observation immediately allows us to answer the question of why the PCET pathway disassembles after every round of turnover: the β -tail completely sequesters the active site such that product dissociation would necessitate β departure (Fig. 2B, S7).

Additionally, this structure suggests how the binding of substrate/effector pairs could facilitate β -tail binding and PCET pathway assembly (See Fig. S1) substrate/effector pair explanation): the β -tail binding pocket simply does not exist as a pocket in the absence of substrate. Substrate itself forms the top of the pocket (Fig. 2B,C) and the right-side of the pocket is formed by a β -hairpin from the α subunit that is known to swing-in toward the active site when substrate-effector pairs are bound (13, 14) (Fig. 2C). Although we do not fully understand why this β -hairpin is swung-in in the presence of cognate substrate-effector pairs, our *E. coli* RNR structures bound with all four of these pairs (CDP/dATP, UDP/dATP, GDP/TTP, and ADP/dGTP) (13) show this swung-in position of the β -hairpin whereas substrate-free or effector-free structures do not. In this cryo-EM structure, we observe the same recognition mode for GDP/TTP as was described before (13) (Fig. S8), and again find a swung-in β -hairpin (Fig. 2C). Residues 643 α –647 α of this hairpin run parallel to residues 343–346 of the β subunit, forming a mini β -sheet, and securing β in position for radical transfer (Fig. 2C, S9).

Further stabilization of the β -tail in its α binding pocket is derived from side chains of β -residues Q349 β and E350 β (Fig. 2C, S9, Table S2). Q349 β contacts PCET residue Y730 α and E350 β contacts K154 α near the effector binding site and S647 α of the β -hairpin. E350 β is known to play a critical role in catalysis (15, 16) and in PCET gating (17), and we can now propose why this is the case. E350 β appears to act as a latch, stabilizing the β -tail and thus the PCET pathway when substrate-effector pairs are bound and the active site is ready for catalysis. Notably, the β -hairpin is also present in class II RNR and shifts inward upon adenosylcobalamin binding to secure this cofactor in position for thyl radical formation (18). Its conservation in class I RNRs was thought to be a vestige, but now appears to be playing an analogous role but with a different radical-cofactor. In both cases, this β -hairpin secures the cofactor for thyl radical generation, which for class II RNR involves positioning adenosylcobalamin for a ~ 3.5 -Å direct radical transfer to Cys, and for class Ia RNR involves positioning a PCET pathway for a ~ 35 -Å remote radical transfer.

The full PCET pathway is structurally resolved in our structure, revealing the position of Y356 β relative to the other key residues along the PCET pathway (Fig. 3A), and showing that the radical-transfer distance is, in fact, extraordinarily long. The total distance from the hydroxyl group of F₃Y122 in β to the thiol group of C439 in α is 32.4 Å, close to the estimated 35–40 Å (4, 5). Several features of this pathway immediately stand out, including the position of W48 β directly in between Y122 β and Y356 β (Fig. 3A). W48 β 's role in PCET (if any) has been enigmatic, since substitution of this residue inactivates RNR at a step prior to PCET, i.e. cofactor formation (19). Now seeing W48 β 's location, positioned at the edge of the β subunit just before Y356 β , prompts us to propose that this residue plays a role in gating PCET to prevent radical loss when the β -tail is not ready to receive a radical species. Such a role will be hard to test experimentally, but could be probed computationally.

Also noteworthy are the differences in distances between PCET residues in β and those in α (Fig. 3A). PCET residues in α are 2.8–3.5 Å apart and side-chains of Y730 α and Y731 α are stacked, consistent with colinear transfer of an electron and a proton as suggested experimentally (20, 21). In contrast, PCET residues in β are 8.0–12.1 Å apart and the side-chain of Y356 β is not stacked with the other PCET residues. These latter distances are consistent with orthogonal electron and proton transfer (22), as well as with electron-transfer distances observed between cofactors within other enzymes (23).

Despite the fact that PCET requires proton donors and acceptors, key PCET residue Y356 β does not make direct contact with any side-chains that could act as proton donor/acceptor. Y356 β is however, surrounded by polar residues that could make through-water contacts (Fig. 3). Water molecules have been implicated in orthogonal proton transfer based on spectroscopic studies (24–26), including the proton transfer to Y122 β by a water molecule on Fe1, which has been proposed to initiate forward PCET (22) (Fig. 1B). Polar residues along the PCET pathway of note include E52 β (Q52 β in this structure), which sits at the nexus of three polar-residue regions (colored yellow, pink and green in Fig 3D). In particular, Q52 β is located directly at the α - β 2 interface where it contacts α residue N322 (Fig. 3B), which in turn is adjacent to Y356 β and R411 α . The latter residue has been shown to affect the conformational flexibility of PCET residue Y731 α (26) (Fig. 3D-pink). Additionally, E52 β was previously shown to be part of a protracted hydrogen-bonding network that extends all the way into the core of the β 2 subunit to the diiron cluster (9) (Fig. 3C, 3D-yellow, S10), and finally this structure shows that Q52 β is next to a loop containing E326 from both α and α' in a region of the structure that leads to bulk solvent (Fig. 3D-green). Whereas α makes the vast majority of interactions with β , α' does help form this part of the α - β interface. Overall, we speculate that E52 β 's essential function (9) is related to the proton transfer component of PCET, and we posit that residues and water molecules in the yellow and pink highlighted regions will be involved in proton transfer, with the residues in the green region providing the route for proton release to solvent.

Thus far, we have focused on α - β interaction, but the α' structure is also worthy of comment. From the biochemical analyses of these RNR constructs ((9), Fig S5), we know that the α 2 β 2 becomes trapped after a single turnover event, i.e. after one α subunit generates product. Consistent with these biochemistry results, α' appears to be the subunit that underwent turnover, whereas α appears to be the one that is in the pre-turnover state

(Fig 4). Briefly, the active site of α (Fig. 4A, S11A) has clear density for a nucleoside diphosphate, and no evidence of a disulfide between C225 and C462, the two redox-active cysteines that become oxidized concomitant with turnover (27). In contrast, α' (Fig. 4B, S11B) has no observable density in the active site corresponding to substrate/product, and the C225/C462 pair has density suggestive of a disulfide, indicating that nucleotide reduction and dithiol oxidation has occurred.

The oxidation of the C225/C462 cysteine pair is accompanied by a ~ 3 Å shift of C α of both C225 and C462 towards the thiyl radical-forming C439 (Fig. 4C). This movement mirrors that observed in previous $\alpha 2$ crystal structures with reduced (13) and oxidized (14) cysteine residues (Fig. S11C, D). Notably, the disulfide generated by catalysis physically occludes the active site (Fig. 4B), likely facilitating product release. However, our structural data show that product cannot leave when the PCET pathway is intact as its exit is blocked (Fig. 2B). Thus, a possible molecular mechanism for PCET pathway dissolution involves disulfide formation ‘pushing’ on product, and product ‘pushing’ on β , causing β to swing from α' to α (Fig. S12). The displacement of β from α' also appears necessary for the re-reduction of the active site disulfide, which is completely buried when the PCET pathway is intact. We observe that α' still has its specificity effector bound, indicating that product loss is not necessarily coupled with that of the substrate-specificity effector.

These structural views of α and α' provide insight into both PCET pathway assembly and disassembly, respectively, suggesting how substrate binding could serve to create the PCET pathway pocket, and how turnover (cysteine oxidation) could send a molecular push enabling pathway disassembly. The elegance of this molecular design has not escaped our attention, with one binding event/catalytic step triggering the next, guiding this enzyme through a series of elaborate conformational rearrangements that produce the requisite deoxynucleotide levels for DNA biosynthesis and repair.

The structure of the $\alpha 2\beta 2$ active complex presented here is the culmination of decades of biochemical and structural studies (3, 7–9, 28–31) (Fig. S13) and provides a powerful example of the utility of unnatural amino acids for trapping transient protein-protein complexes. It also provides an illustration of the benefit of cryo-EM for studying transient enzyme complexes. Use of the doubly-substituted $\beta 2$ slowed complex dissociation to the minute time scale of cryo-EM grid generation, but not to the hour-day time scale that crystallization requires. Without the resolution revolution that the cryo-EM field is experiencing, this work would not have been possible. These resulting structural data will serve as a launching point towards answering other long sought-after questions about both biological PCET and RNR.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements:

We thank Dr. E.J. Brignole for his invaluable advice in preparing our samples for cryo-EM data collection and subsequent data processing, A. Kim for performing the activity assays and radical quantifications, and Q. Lin for

providing the E52Q/F3Y122- β 2 protein that was essential for the success of this study. Cryo-EM data was collected at the UMass Medical School Worcester Cryo-EM Facility with the help of Dr. Kangkang Song and Dr. Chen Xu.

Funding: This work was supported by the National Institutes of Health grants R35 GM126982 (to C.L.D.), R01 GM29595 (to J.S.), and F32 GM123596 (A.T.T.), and by a David H. Koch Graduate Fellowship to G.K. CLD is an HHMI Investigator.

References and Notes:

1. Aye Y, Li M, Long MJ, Weiss RS, Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. *Oncogene* 34, 2011–2021 (2015). [PubMed: 24909171]
2. Licht S, Gerfen GJ, Stubbe J, Thiyl radicals in ribonucleotide reductases. *Science* 271, 477–481 (1996). [PubMed: 8560260]
3. Minnihan EC, Nocera DG, Stubbe J, Reversible, long-range radical transfer in *E. coli* class Ia ribonucleotide reductase. *Acc Chem Res* 46, 2524–2535 (2013). [PubMed: 23730940]
4. Seyedsayamdost MR, Chan CT, Mugnaini V, Stubbe J, Bennati M, PELDOR spectroscopy with DOPA-beta2 and NH2Y-alpha2s: distance measurements between residues involved in the radical propagation pathway of *E. coli* ribonucleotide reductase. *J Am Chem Soc* 129, 15748–15749 (2007). [PubMed: 18047343]
5. Uhlin U, Eklund H, Structure of ribonucleotide reductase protein R1. *Nature* 370, 533–539 (1994). [PubMed: 8052308]
6. Nordlund P, Sjoberg BM, Eklund H, Three-dimensional structure of the free radical protein of ribonucleotide reductase. *Nature* 345, 593–598 (1990). [PubMed: 2190093]
7. Minnihan EC et al., Generation of a stable, aminotyrosyl radical-induced alpha2beta2 complex of *Escherichia coli* class Ia ribonucleotide reductase. *Proc Natl Acad Sci U S A* 110, 3835–3840 (2013). [PubMed: 23431160]
8. Ando N et al., Structural interconversions modulate activity of *Escherichia coli* ribonucleotide reductase. *Proc Natl Acad Sci U S A* 108, 21046–21051 (2011). [PubMed: 22160671]
9. Lin Q et al., Glutamate 52-beta at the alpha/beta subunit interface of *Escherichia coli* class Ia ribonucleotide reductase is essential for conformational gating of radical transfer. *J Biol Chem* 292, 9229–9239 (2017). [PubMed: 28377505]
10. Artin E et al., Insight into the mechanism of inactivation of ribonucleotide reductase by gemcitabine 5'-diphosphate in the presence or absence of reductant. *Biochemistry* 48, 11622–11629 (2009). [PubMed: 19899770]
11. Uppsten M, Farnegardh M, Domkin V, Uhlin U, The first holocomplex structure of ribonucleotide reductase gives new insight into its mechanism of action. *J Mol Biol* 359, 365–377 (2006). [PubMed: 16631785]
12. Thomas WC et al., Convergent allostery in ribonucleotide reductase. *Nat Commun* 10, 2653 (2019). [PubMed: 31201319]
13. Zimanyi CM, Chen PY, Kang G, Funk MA, Drennan CL, Molecular basis for allosteric specificity regulation in class Ia ribonucleotide reductase from *Escherichia coli*. *Elife* 5, e07141 (2016). [PubMed: 26754917]
14. Eriksson M et al., Binding of allosteric effectors to ribonucleotide reductase protein R1: reduction of active-site cysteines promotes substrate binding. *Structure* 5, 1077–1092 (1997). [PubMed: 9309223]
15. Climent I, Sjoberg BM, Huang CY, Site-directed mutagenesis and deletion of the carboxyl terminus of *Escherichia coli* ribonucleotide reductase protein R2. Effects on catalytic activity and subunit interaction. *Biochemistry* 31, 4801–4807 (1992). [PubMed: 1591241]
16. Ravichandran K et al., Glutamate 350 Plays an Essential Role in Conformational Gating of Long-Range Radical Transport in *Escherichia coli* Class Ia Ribonucleotide Reductase. *Biochemistry* 56, 856–868 (2017). [PubMed: 28103007]
17. Greene BL, Stubbe J, Nocera DG, Photochemical Rescue of a Conformationally Inactivated Ribonucleotide Reductase. *J Am Chem Soc* 140, 15744–15752 (2018). [PubMed: 30347141]

18. Sintchak MD, Arjara G, Kellogg BA, Stubbe J, Drennan CL, The crystal structure of class II ribonucleotide reductase reveals how an allosterically regulated monomer mimics a dimer. *Nat Struct Biol* 9, 293–300 (2002). [PubMed: 11875520]
19. Bollinger JM et al., Mechanism of Assembly of the Tyrosyl Radical-Diiron(III) Cofactor of *E. coli* Ribonucleotide Reductase. 3. Kinetics of the Limiting Fe²⁺ Reaction by Optical, EPR, and Moessbauer Spectroscopies. *J Am Chem Soc* 116, 8024–8032 (1994).
20. Argirevic T, Riplinger C, Stubbe J, Neese F, Bennati M, ENDOR spectroscopy and DFT calculations: evidence for the hydrogen-bond network within alpha2 in the PCET of *E. coli* ribonucleotide reductase. *J Am Chem Soc* 134, 17661–17670 (2012). [PubMed: 23072506]
21. Nick TU et al., Hydrogen bond network between amino acid radical intermediates on the proton-coupled electron transfer pathway of *E. coli* alpha2 ribonucleotide reductase. *J Am Chem Soc* 137, 289–298 (2015). [PubMed: 25516424]
22. Worsdorfer B et al., Function of the diiron cluster of *Escherichia coli* class Ia ribonucleotide reductase in proton-coupled electron transfer. *J Am Chem Soc* 135, 8585–8593 (2013). [PubMed: 23676140]
23. Reece SY, Nocera DG, Proton-coupled electron transfer in biology: results from synergistic studies in natural and model systems. *Annu Rev Biochem* 78, 673–699 (2009). [PubMed: 19344235]
24. Nick TU, Ravichandran KR, Stubbe J, Kasanmascheff M, Bennati M, Spectroscopic Evidence for a H Bond Network at Y356 Located at the Subunit Interface of Active *E. coli* Ribonucleotide Reductase. *Biochemistry* 56, 3647–3656 (2017). [PubMed: 28640584]
25. Greene BL, Taguchi AT, Stubbe J, Nocera DG, Conformationally Dynamic Radical Transfer within Ribonucleotide Reductase. *J Am Chem Soc* 139, 16657–16665 (2017). [PubMed: 29037038]
26. Kasanmascheff M, Lee W, Nick TU, Stubbe J, Bennati M, Radical transfer in *E. coli* ribonucleotide reductase: a NH₂Y731/R411A-alpha mutant unmasks a new conformation of the pathway residue 731. *Chem Sci* 7, 2170–2178 (2016). [PubMed: 29899944]
27. Mao SS et al., A model for the role of multiple cysteine residues involved in ribonucleotide reduction: amazing and still confusing. *Biochemistry* 31, 9733–9743 (1992). [PubMed: 1382592]
28. Yokoyama K, Uhlin U, Stubbe J, A hot oxidant, 3-NO₂Y122 radical, unmasks conformational gating in ribonucleotide reductase. *J Am Chem Soc* 132, 15368–15379 (2010). [PubMed: 20929229]
29. Salowe SP, Ator MA, Stubbe J, Products of the inactivation of ribonucleoside diphosphate reductase from *Escherichia coli* with 2'-azido-2'-deoxyuridine 5'-diphosphate. *Biochemistry* 26, 3408–3416 (1987). [PubMed: 3307907]
30. Ravichandran KR, Minnihan EC, Wei Y, Nocera DG, Stubbe J, Reverse Electron Transfer Completes the Catalytic Cycle in a 2,3,5-Trifluorotyrosine-Substituted Ribonucleotide Reductase. *J Am Chem Soc* 137, 14387–14395 (2015). [PubMed: 26492582]
31. Bennati M et al., EPR distance measurements support a model for long-range radical initiation in *E. coli* ribonucleotide reductase. *J Am Chem Soc* 127, 15014–15015 (2005). [PubMed: 16248626]
32. Oyala PH et al., Biophysical Characterization of Fluorotyrosine Probes Site-Specifically Incorporated into Enzymes: *E. coli* Ribonucleotide Reductase As an Example. *J Am Chem Soc* 138, 7951–7964 (2016). [PubMed: 27276098]
33. Ge J, Yu G, Ator MA, Stubbe J, Pre-steady-state and steady-state kinetic analysis of *E. coli* class I ribonucleotide reductase. *Biochemistry* 42, 10071–10083 (2003). [PubMed: 12939135]
34. Zheng SQ et al., MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat Methods* 14, 331–332 (2017). [PubMed: 28250466]
35. Penczek PA et al., CTER-rapid estimation of CTF parameters with error assessment. *Ultramicroscopy* 140, 9–19 (2014). [PubMed: 24562077]
36. Moriya T et al., High-resolution Single Particle Analysis from Electron Cryo-microscopy Images Using SPHIRE. *J Vis Exp*, (2017).
37. Bepler T et al., Positive-unlabeled convolutional neural networks for particle picking in cryo-electron micrographs. *Res Comput Mol Biol* 10812, 245–247 (2018). [PubMed: 29707703]
38. Zivanov J et al., New tools for automated high-resolution cryo-EM structure determination in RELION-3. *Elife* 7, e42166 (2018). [PubMed: 30412051]

39. Rohou A, Grigorieff N, CTFIND4: Fast and accurate defocus estimation from electron micrographs. *J Struct Biol* 192, 216–221 (2015). [PubMed: 26278980]
40. Kucukelbir A, Sigworth FJ, Tagare HD, Quantifying the local resolution of cryo-EM density maps. *Nat Methods* 11, 63–65 (2014). [PubMed: 24213166]
41. Goddard TD et al., UCSF ChimeraX: Meeting modern challenges in visualization and analysis. *Protein Sci* 27, 14–25 (2018). [PubMed: 28710774]
42. Emsley P, Lohkamp B, Scott WG, Cowtan K, Features and development of Coot. *Acta Crystallogr D* 66, 486–501 (2010). [PubMed: 20383002]
43. Afonine PV et al., Real-space refinement in PHENIX for cryo-EM and crystallography. *Acta Crystallogr D Struct Biol* 74, 531–544 (2018). [PubMed: 29872004]
44. Williams CJ et al., MolProbity: More and better reference data for improved all-atom structure validation. *Protein Sci* 27, 293–315 (2018). [PubMed: 29067766]
45. Barad BA et al., EMRinger: side chain-directed model and map validation for 3D cryo-electron microscopy. *Nat Methods* 12, 943–946 (2015). [PubMed: 26280328]
46. Morin A et al., Collaboration gets the most out of software. *Elife* 2, e01456 (2013). [PubMed: 24040512]
47. Brown NC, Reichard P, Role of effector binding in allosteric control of ribonucleoside diphosphate reductase. *J Mol Biol* 46, 39–55 (1969). [PubMed: 4902212]

substrate GDP and specificity effector TTP. Model colors are as in Fig. 1C with cryo-EM density shown in transparent grey.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Fig. 2: Fully visualized β -tail extends deep into the α active site.

A) Missing β residues 342–362 modeled into cryo-EM density (grey mesh, threshold set to 0.0249). B) Slice through space filling representation showing tight packing between subunits which blocks solvent accessibility. C) β -C-terminus extends up to substrate-binding site in α . Regions of α that contact β -tail are displayed. Substrate GDP and effector TTP are shown in sticks, separated by the specificity loop, labeled at position R298. Inset: β -hairpin of α shifts 5-Å toward the active site upon substrate and effector binding and the ordering of the specificity loop. Three α 2 structures were aligned to highlight movement of this β -hairpin: substrate-free α 2 (pink, PDB 2R1R (14)), substrate/effector-bound α 2 from inhibited α 4 β 4 (purple, PDB 5CNV (13)), and substrate-bound α 2 from our structure of active α 2 β 2 (blue).




Fig. 3: The interface region of the $\alpha_2\beta_2$ complex.

A) Key residues that are involved in PCET, including Y356, are shown with distances between them in angstroms. W48 is shown in partial transparency due to uncertainty regarding its direct participation in PCET. Colors are as in Fig. 1C. B) Positioning of Q52 of β with respect to PCET pathway (dashed lines). The Q52 side-chain is 2.5 Å from the side-chain of N322, 6.9 Å from the side-chain hydroxyl of PCET residue Y356, and 5.2 Å from the C4 position of the indole ring of W48 in β . C) Superimposition of higher-resolution structure of β (yellow, PDB 5C14 (32)) onto the cryo-EM structure (Fig. S10) shows that E52 β connects the diiron site to α residue N322 via a hydrogen-bonding network (dashed lines) that involves several waters (red spheres). D) Regions surrounding E/Q52 are very

polar. See text for description of colored regions. Arrow indicates direction towards bulk solvent.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Fig. 4:
 The active sites of α and α' are structurally different. A) In α , density (shown in mesh) indicates the presence of substrate GDP and the absence of a disulfide between C225 and C462. Catalytic residues C439 and E441 are shown for context. B) In α' , density for GDP is absent and density is present indicative of a disulfide. C) A ~ 3 Å shift of C α of both C225 and C462 toward C439 and E441 within the active site of α' is consistent with a disulfide between C225-C462, suggesting a post-turnover state. Arrow represents the directionality of this movement between α and α' . Density threshold for cryo-EM map in A) and B) were set to same level (0.0384).